Acquires Rights to Rufinamide in Anxiety Disorders and Bipolar Mood Disorders
Synosia Therapeutics today announced that it has signed an exclusive, worldwide licensing agreement (outside of Japan) with Novartis Pharma AG to develop and commercialise rufinamide for the treatment of anxiety disorders and bipolar mood disorders. This is the second
4 min read